X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Bioasis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 23, 2023
Details:
Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (CNS) disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Biodexa Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 13, 2022
Details:
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: MTX110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
